Clinical Trials · NCT02319837

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Name: Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Active Not Recruiting
Sponsor: Pfizer
Enrollment: 1,068
Start date: Dec 2014
Locations: 255 sites, 17 countries
Primary endpoint: Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide

View Gonadorelin compound reference